SELLAS Life Sciences Group, Inc. - Common Stock (SLS)
1.5000
0.00 (0.00%)
Sellas Life Sciences Group Inc is a biotechnology company focused on the development of innovative immunotherapies for the treatment of cancer
The company is dedicated to advancing its therapeutic candidates through clinical trials, aiming to address unmet medical needs in oncology. By leveraging proprietary technology and scientific expertise, Sellas seeks to provide patients with effective treatment options that harness the body’s immune system to target and combat cancerous cells. Their pipeline includes various late-stage candidates designed to offer new hope for better outcomes in cancer care.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83 billion in 2024, and is expected to reach USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the forecast period (2024-2029). The report said: “Key factors propelling the growth of this market are the high incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development and increasing investments in research and development by pharmaceutical companies. According to the American Cancer Society, it is estimated that there will be 60,650 new leukemia cancer cases, of which 24,000 are expected to die in 2022 in the US. In addition, according to the same source, 20,050 new cases of acute myeloid leukemia (AML) are estimated in 2022 in the US. It will lead to increased adoption of AML therapies. The rising prevalence of AML in developed countries such as the US is expected to drive this market's growth. Furthermore, with the rising investment in research and development, there is an increasing number of clinical trials conducted to demonstrate the effectiveness of the drugs. It is expected to drive the market over the forecast period.” Active biotech and pharma companies in the markets this week include Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), Bio-Path Holdings, Inc., (NASDAQBPTH), Longeveron NASDAQ: LGVNNASDAQLGVN)(NASDAQ: SLSNASDAQSLS, Bristol Myers Squibb (NYSE: BMYNYSE).
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&P 500 also fell, dropping, 0.64% to 5,117.35.
Shares of Jabil Inc. (NYSEJBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates.
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded down 0.37% to 38,761.74 while the NASDAQ fell 0.95% to 15,974.83. The S&P 500 also fell, dropping, 0.62% to 5,118.35.
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Friday. Following the market opening Friday, the Dow traded down 0.28% to 38,797.24 while the NASDAQ fell 0.67% to 16,020.07. The S&P 500 also fell, dropping, 0.58% to 5,120.59.
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining over 100 points on Thursday. The Dow traded up 0.33% to 37,554.56 while the NASDAQ fell 0.10% to 14,578.04. The S&P 500 also rose, gaining, 0.09% to 4,708.93.
Shares of Mobileye Global Inc. (NASDAQMBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining around 200 points on Thursday. The Dow traded up 0.55% to 37,635.05 while the NASDAQ rose 0.05% to 14,599.10. The S&P 500 also rose, gaining, 0.28% to 4,718.19.
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.15% to 37,487.49 while the NASDAQ fell 0.27% to 14,553.12. The S&P 500 also fell, dropping, 0.01% to 4,704.42.
